Abstract

The overall objective of this contract is to evaluate control measures for infectious diseases other than AIDS. There are still many infectious diseases for which effective and highly safe vaccines and therapies have yet to be developed. Additionally, for some diseases improved vaccines are needed that will prevent infection and disease in age groups not currently protected and that will offer increased safety. New vaccine and drug candidates continue to be developed, spurred on by advances in the basic sciences. The capacity to evaluate these new and improved vaccine and therapy candidates in an efficient and expeditious manner is an essential element of the efforts of the Division of Microbiology and Infectious Diseases (DMID) of the National Institute of Allergy and Infectious Diseases (NIAID)). This contract for a Vaccine and Treatment Evaluation Unit (VTEU) is an integral part of these efforts and supports Phase I and Phase II clinical trials of bacterial and viral vaccines, other biologicals, and drugs as preventative and therapeutic measures against infectious diseases in people of all ages and risk categories. In selected circumstances, Phase III vaccine trials may also be undertaken. Also of importance is the epidemiologic surveillance of pathogens that are of special interest to NIAID, and capacity to undertake limited, relevant, basic and preclinical research directly linked to vaccine biology and immunology.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research and Development Contracts (N01)
Project #
N01AI045248-017
Application #
6346785
Study Section
Project Start
1994-09-30
Project End
2001-09-29
Budget Start
2000-06-20
Budget End
2001-01-31
Support Year
Fiscal Year
2000
Total Cost
$500,000
Indirect Cost

  Institution

Name
University of Rochester
Department
Internal Medicine/Medicine
Type
Schools of Dentistry
DUNS #
208469486
City
Rochester
State
NY
Country
United States
Zip Code
14627

  Publications

Bernstein, David I; El Sahly, Hana M; Keitel, Wendy A et al. (2011) Safety and immunogenicity of a candidate parvovirus B19 vaccine. Vaccine 29:7357-63
Hoft, Daniel F; Babusis, Elizabeth; Worku, Shewangizaw et al. (2011) Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis 204:845-53
Park, In H; Moore, Matthew R; Treanor, John J et al. (2008) Differential effects of pneumococcal vaccines against serotypes 6A and 6C. J Infect Dis 198:1818-22
Bernstein, David I; Yan, Lihan; Treanor, John et al. (2003) Effect of yearly vaccinations with live, attenuated, cold-adapted, trivalent, intranasal influenza vaccines on antibody responses in children. Pediatr Infect Dis J 22:28-34
Kirmani, Khaver I; Lofthus, Geraldine; Pichichero, Michael E et al. (2002) Seven-year follow-up of vaccine response in extremely premature infants. Pediatrics 109:498-504
Treanor, John; Keitel, Wendy; Belshe, Robert et al. (2002) Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults. Vaccine 20:1099-105
Vedhara, Kavita; McDermott, Michael P; Evans, Thomas G et al. (2002) Chronic stress in nonelderly caregivers: psychological, endocrine and immune implications. J Psychosom Res 53:1153-61
Frey, Sharon E; Couch, Robert B; Tacket, Carol O et al. (2002) Clinical responses to undiluted and diluted smallpox vaccine. N Engl J Med 346:1265-74
Piedra, Pedro A; Yan, Lihan; Kotloff, Karen et al. (2002) Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children. Pediatrics 110:662-72
Lin, J S; Park, M K; Nahm, M H (2001) Chromogenic assay measuring opsonophagocytic killing capacities of antipneumococcal antisera. Clin Diagn Lab Immunol 8:528-33

Showing the most recent 10 out of 26 publications